Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04560738 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04560738: Completed Phase 1 study, sponsored by Celgene.
NCT04560738 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04560738, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of \[14C\]-CC-92480 and to evaluate the safety and tolerability of \[14C\]-CC-92480 following a single oral dose of \[14C\]-CC-92480.
Primary Outcome
The total recovery of radioactivity (RA) will be computed as the sum of the cumulative excretion (as % dose) in urine and feces (and vomit, if applicable).
Interventions
- DRUG [14C]-CC-92480
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-05-13 |
| Phase | Phase 1 |
What the finished NCT04560738 record still lists
NCT04560738 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]-CC-92480 is the first listed.
NCT04560738 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04560738 about?
NCT04560738 is a clinical study titled "A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants". This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of \[14C\]-CC-92480 and to evaluate the safety and tolerability of \[14C\]-CC-92480 following a single oral dose of \[14C\]-CC-9248...
What is the current status of trial NCT04560738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-10-15. Estimated completion is 2021-05-13.
What interventions are being tested in trial NCT04560738?
The interventions under investigation include: [14C]-CC-92480 (DRUG).
Who is sponsoring clinical trial NCT04560738?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04560738's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI